The DOI matches its Crossref record; 25 of the 25 references it cites were found in a registry or an index.
Effects of acute and repeated treatment with the biased mu opioid receptor agonist TRV130 (oliceridine) on measures of antinociception, gastrointestinal function, and abuse liability in rodents
Open accessAbstract
Rationale: TRV130 (oliceridine; N-[(3-methoxythiophen-2-yl)methyl]-2-[(9R)-9-pyridin-2-yl-6-oxaspiro[4.5]decan-9-yl]ethanamine) is a novel mu opioid receptor (MOR) agonist that preferentially activates G-protein versus β-arrestin signaling pathways coupled to MORs. Prevailing evidence suggests that TRV130 and other G-protein-biased MOR agonists may produce therapeutic analgesic effects with reduced adverse effects compared to existing MOR agonists. Objectives: This study compared the effects of acute and repeated TRV130 administration on measures of antinociception, gastrointestinal function, and abuse liability in rodents. We hypothesized that TRV130 would produce robust and sustained antinociception and abuse-related effects during repeated treatment, but that tolerance would develop to gastrointestinal inhibition. Methods: Antinociception was assessed using a warm-water tail-withdrawal procedure in mice. Gastrointestinal function was assessed in mice using an in vivo measure of fecal output and in vitro assays of colonic propulsion and of colon and ileum circular muscle contraction. Abuse liability was assessed in rats using an intracranial self-stimulation (ICSS) procedure. (+)-TRV130 was administered with acute and repeated dosing regimens, and (–)-TRV130 was also examined in the ICSS procedure to assess stereoselectivity. Results: Acute (+)-TRV130 treatment produced robust antinociception, complete inhibition of gastrointestinal function, and weak abuse-related effects.…
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“Thus, data to date suggest that such non-arrestin 3signaling drugs retain undesirable constipating and abuse-related effects with repeated exposure, despite their bias for G protein signaling (Altarifi et al., 2017).”
From Drug Addiction: Hyperkatifeia/Negative Reinforcement as a Framework for Medications Development (2021) · cites this paper as Altarifi et al., 2017
Citations
Cites
β-Arrestins and Cell Signaling
DeWire, S. M., Ahn, S., Lefkowitz, R. J., & Shenoy, S. K. (2007) · Annual Review of Physiology · doi:10.1146/annurev.physiol.69.022405.154749 · Cited by 1,397 · cited 1×
“…contribution to acute MOR agonist effects, β-arrestin recruitment is an early step in MOR desensitization and internalization, and these processes ultimately contribute to adaptions in receptor function and drug effects during chronic treatment (DeWire et al., 2007; Raehal and Bohn, 2014).”
BackgroundStructure-based discovery of opioid analgesics with reduced side effects
Manglik, A., Lin, H., Aryal, D. K., McCorvy, J. D., Dengler, D., Corder, G., Levit, A., Kling, R. C., Bernat, V., Hübner, H., et al. (2016) · Nature · doi:10.1038/nature19112 · Cited by 944 · cited 3×
“This evidence for abuse liability by (+)-TRV130 contrasts with a recent report that a single dose of (±)-TRV130 failed to produce a conditioned place preference in mice (Manglik et al., 2016).”
BackgroundResultInfluentialU-50,488: a selective and structurally novel non-Mu (kappa) opioid agonist.
Vonvoigtlander, P. F., Lahti, R. A., & Ludens, J. H. (1983) · The Journal of Pharmacology and Experimental Therapeutics · doi:10.1016/s0022-3565(25)33422-1 · Cited by 805 · cited 1×
“This type of treatment regimen has been used previously to assess antinociceptive tolerance in mice (e.g. Vonvoigtlander et al., 1983), and doses of (+)-TRV130 and morphine selected as repeated and challenge doses were based on prior publications describing potency and effectiveness of these drugs…”
MethodDeWire, S. M., Yamashita, D. S., Rominger, D. H., Liu, G., Cowan, C. L., Graczyk, T. M., Chen, X.-T., Pitis, P. M., Gotchev, D., Yuan, C., et al. (2013) · The Journal of Pharmacology and Experimental Therapeutics · doi:10.1124/jpet.112.201616 · Cited by 647 · cited 8×
“5]decan-9-yl] ethanamine) is a novel MOR agonist that selectively activates MOR signaling via G-proteins as opposed to β-arrestins, and this bias toward G-protein signaling has been linked to bias in production of MOR-mediated effects on physiology and behavior (Chen et al., 2013; DeWire et al., 2013; Soergel et al.,…”
BackgroundResultInfluentialMorphine Side Effects in β-Arrestin 2 Knockout Mice
Raehal, K. M., Walker, J. K. L., & Bohn, L. M. (2005) · The Journal of Pharmacology and Experimental Therapeutics · doi:10.1124/jpet.105.087254 · Cited by 626 · cited 1×
“First, morphine-induced constipation was reduced in β-arrestin 2 knockout mice relative to their wild-type controls (Raehal et al., 2005).”
BackgroundBiased ligands at G-protein-coupled receptors: promise and progress
Violin, J. D., Crombie, A. L., Soergel, D. G., & Lark, M. W. (2014) · Trends in Pharmacological Sciences · doi:10.1016/j.tips.2014.04.007 · Cited by 363 · cited 3×
“The present results confirm and extend previous evidence to indicate that TRV130 produces antinociception in rodents and analgesic effects in humans (Chen et al., 2013; DeWire et al., 2013; Soergel et al., 2014a,b; Violin et al., 2014).”
BackgroundResultSoergel, D. G., Subach, R. A., Burnham, N., Lark, M. W., James, I. E., Sadler, B. M., Skobieranda, F., Violin, J. D., & Webster, L. R. (2014) · Pain · doi:10.1016/j.pain.2014.06.011 · Cited by 262 · cited 4×
“However, TRV130 increased morphine-like subjective effects in humans (Soergel et al., 2014a), and β-arrestin 2 knockout enhanced the rewarding effects of morphine in a placeconditioning procedure in mice (Bohn et al., 2003).”
BackgroundResultInfluentialEnhanced Rewarding Properties of Morphine, but not Cocaine, in βarrestin-2 Knock-Out Mice
Bohn, L. M., Gainetdinov, R. R., Sotnikova, T. D., Medvedev, I. O., Lefkowitz, R. J., Dykstra, L. A., & Caron, M. G. (2003) · The Journal of Neuroscience · doi:10.1523/jneurosci.23-32-10265.2003 · Cited by 210 · cited 3×
“However, TRV130 increased morphine-like subjective effects in humans (Soergel et al., 2014a), and β-arrestin 2 knockout enhanced the rewarding effects of morphine in a placeconditioning procedure in mice (Bohn et al., 2003).”
BackgroundIntracranial Self-Stimulation to Evaluate Abuse Potential of Drugs
Negus, S. S., & Miller, L. L. (2014) · Pharmacological Reviews · doi:10.1124/pr.112.007419 · Cited by 209 · cited 3×
“For example, intracranial selfstimulation (ICSS) is one experimental procedure that has been used for preclinical abuse liability assessment (Negus and Miller, 2014).”
BackgroundMethodSelf-citationChen, X.-T., Pitis, P., Liu, G., Yuan, C., Gotchev, D., Cowan, C. L., Rominger, D. H., Koblish, M., DeWire, S. M., Crombie, A. L., et al. (2013) · Journal of Medicinal Chemistry · doi:10.1021/jm4010829 · Cited by 208 · cited 2×
“…selectively activates MOR signaling via G-proteins as opposed to β-arrestins, and this bias toward G-protein signaling has been linked to bias in production of MOR-mediated effects on physiology and behavior (Chen et al., 2013; DeWire et al., 2013; Soergel et al., 2014a,b; Viscusi et al., 2016).”
BackgroundResult
Cited by
G protein-coupled receptors (GPCRs): advances in structures, mechanisms and drug discovery
Zhang, M., Chen, T., Lu, X., Lan, X., Chen, Z., & Lu, S. (2024) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-024-01803-6 · Cited by 491
Gillis, A., Gondin, A. B., Kliewer, A., Sanchez, J., Lim, H. D., Alamein, C., Manandhar, P., Santiago, M., Fritzwanker, S., Schmiedel, F., et al. (2020) · Science Signaling · doi:10.1126/scisignal.aaz3140 · Cited by 336
“Further studies have reinforced that oliceridine induces constipation and abuse-related effects in rodents (12, 13), and although it still induces respiratory depression and constipation in humans, these side effects may be reduced when compared to morphine, giving a potentially wider therapeutic window (14, 15).”
BackgroundOpioid receptors: drivers to addiction?
Darcq, E., & Kieffer, B. L. (2018) · Nature Reviews Neuroscience · doi:10.1038/s41583-018-0028-x · Cited by 352
Drug Addiction: Hyperkatifeia/Negative Reinforcement as a Framework for Medications Development
Koob, G. F. (2021) · Pharmacological Reviews · doi:10.1124/pharmrev.120.000083 · Cited by 337
“Thus, data to date suggest that such non–arrestin 3signaling drugs retain undesirable constipating and abuse-related effects with repeated exposure, despite their bias for G protein signaling (Altarifi et al., 2017).”
BackgroundBiased Receptor Signaling in Drug Discovery
Kenakin, T. (2019) · Pharmacological Reviews · doi:10.1124/pr.118.016790 · Cited by 294
“However, repeated treatment failed to produce tolerance seen with morphine (Altarifi et al., 2017).”
Background
Metadata
- Authors
- Altarifi, A. A., David, B., Muchhala, K. H., Blough, B. E., Akbarali, H., & Negus, S. S.
- Affiliations
- Jordan University of Science and Technology (JO)
- Virginia Commonwealth University (US)
- RTI International (US)
- Corresponding author
- Altarifi, Ahmad A
- Venue
- Journal of Psychopharmacology
- Publisher
- SAGE Publications
- Published
- 2017-02-01
- Volume
- 31
- Issue
- 6
- Pages
- 730-739
- ISSN
- 0269-8811 (ISSN-L)
- 1461-7285
- PMC
- PMC5646680
- OpenAlex
- W2584711061
- Cited by
- 166
- References
- 25
- Citations by year
- 2026: 12 · 2025: 8 · 2024: 6 · 2023: 10 · 2022: 17 · 2021: 31 · 2020: 25 · 2019: 33 · 2018: 20 · 2017: 4
- FWCI
- 10.98
- Type
- journal article
- Language
- en
- Open access
- green
- www.ncbi.nlm.nih.gov
- Licence
- journals.sagepub.com/page/policies/text-and-data-mining-license (tdm)
- Locations
- Journal of Psychopharmacology (publishedVersion)
- PubMed (publishedVersion)
- Europe PMC (PubMed Central) (acceptedVersion)
- PubMed Central (acceptedVersion)
- Funders
- National Institutes of Health (R01 NS070715, R01DA024009, T32DA007027)
- Topics
- Life Sciences › Neuroscience › Cellular and Molecular Neuroscience › Neuropeptides and Animal Physiology
- Health Sciences › Medicine › Physiology (medical) › Pain Mechanisms and Treatments
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Receptor Mechanisms and Signaling
- Keywords
- TRV130, oliceridine, mu-opioid receptor agonists, β-arrestin signaling, antinociception, opioid tolerance, gastrointestinal function, constipation, abuse liability, stereoselectivity, intracranial self-stimulation, colonic propulsion, circular muscle contraction, morphine comparison
- MeSH terms
- beta-Arrestins, Analgesics, Analgesics, Opioid, Animals, Gastrointestinal Agents, Male, Rodentia, Spiro Compounds, Thiophenes, Signal Transduction, Rats, Sprague-Dawley, Receptors, Opioid, mu, Gastrointestinal Tract, Mice
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Effects of acute and repeated treatment with the biased mu opioid receptor agonist TRV130 (oliceridine) on measures of antinociception, gastrointestinal function, and abuse liability in rodents. https://app.cochat.ai/papers/10.1177/0269881116689257
- The paper
- Altarifi, A. A., David, B., Muchhala, K. H., Blough, B. E., Akbarali, H., & Negus, S. S. (2017). Effects of acute and repeated treatment with the biased mu opioid receptor agonist TRV130 (oliceridine) on measures of antinociception, gastrointestinal function, and abuse liability in rodents. Journal of Psychopharmacology. https://doi.org/10.1177/0269881116689257
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.